Welcome
Empowering Rapid Tests for Allergy diagnosis
Unlock the potential of rapid test with Allerdia's novel platform for allergy diagnosis
About Allerdia Inc
Our History
Our Technology
Our Technology
Allerdia Inc, a Delaware Corporation operated in Los Angeles, California, established in 2019, in response to the exponential surge of allergy prevalence and need for more readily accessible, accurate, rapid, cost-effective and Point-Of-Care enabled diagnostics for accurate allergy diagnosis
Our Technology
Our Technology
Our Technology
Allerdia dedicates to develop and commercialize a novel rapid immunosensor-based allergic IgE diagnostic test, termed as Reverse-Lateral Flow ImmunoAssay (R-LFIA), a patented technology platform (PCT/US2020/054027), for sensitive & specific allergy diagnosis using a rapid test format for Point-Of-Care use.
Our Impact
Our Technology
Our Impact
With a small drop of serum sample or capillary blood, our device utilizing R-LFIA, can highly sensitively and specifically detect allergic IgE for allergy diagnosis within 15 minutes on site. Allerdia's multiplex IgE detection test is capable of simultaneously detecting 10 types of allergic IgE using single sample input.
Welcome to Allerdia Inc
We are an allergy diagnostic company specializing in innovative solutions for healthcare. Our cutting-edge technology is designed to improve lives and healthcare.